The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review

Overview

Journal Drugs

Specialty Pharmacology

Date 2024 Oct 29

PMID 39467989

Authors

Carmen Hidalgo-Tenorio

German Bou

Antonio Oliver

Montserrat Rodriguez-Aguirregabiria

Miguel Salavert

Luis Martinez-Martinez

Affiliations

Soon will be listed here.

Abstract

Gram-negative multidrug-resistant (MDR) bacteria, including Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa, pose a significant challenge in clinical practice. Infections caused by metallo-β-lactamase (MBL)-producing Gram-negative organisms, in particular, require careful consideration due to their complexity and varied prevalence, given that the microbiological diagnosis of these pathogens is intricate and compounded by challenges in assessing the efficacy of anti-MBL antimicrobials. We discuss both established and new approaches in the treatment of MBL-producing Gram-negative infections, focusing on 3 strategies: colistin; the recently approved combination of aztreonam with avibactam (or with ceftazidime/avibactam); and cefiderocol. Despite its significant activity against various Gram-negative pathogens, the efficacy of colistin is limited by resistance mechanisms, while nephrotoxicity and acute renal injury call for careful dosing and monitoring in clinical practice. Aztreonam combined with avibactam (or with avibactam/ceftazidime if aztreonam plus avibactam is not available) exhibits potent activity against MBL-producing Gram-negative pathogens. Cefiderocol in monotherapy is effective against a wide range of multidrug-resistant organisms, including MBL producers, and favorable clinical outcomes have been observed in various clinical trials and case series. After examining scientific evidence in the management of infections caused by MBL-producing Gram-negative bacteria, we have developed a comprehensive clinical algorithm to guide therapeutic decision making. We recommend reserving colistin as a last-resort option for MDR Gram-negative infections. Cefiderocol and aztreonam/avibactam represent favorable options against MBL-producing pathogens. In the case of P. aeruginosa with MBL-producing enzymes and with difficult-to-treat resistance, cefiderocol is the preferred option. Further research is needed to optimize treatment strategies and minimize resistance.

References

Hernando-Amado S, Coque T, Baquero F, Martinez J . Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat Microbiol. 2019; 4(9):1432-1442. DOI: 10.1038/s41564-019-0503-9. View

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017; 18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3. View

Yahav D, Giske C, Gramatniece A, Abodakpi H, Tam V, Leibovici L . New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). PMC: 7667665. DOI: 10.1128/CMR.00115-20. View

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A . Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). PMC: 5967687. DOI: 10.1128/CMR.00079-17. View

Zakhour J, El Ayoubi L, Kanj S . Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects. Expert Rev Anti Infect Ther. 2024; 22(4):189-201. DOI: 10.1080/14787210.2024.2311213. View

Nordmann P, Poirel L, Dortet L . Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2012; 18(9):1503-7. PMC: 3437707. DOI: 10.3201/eid1809.120355. View

Dortet L, Poirel L, Nordmann P . Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol. 2012; 50(11):3773-6. PMC: 3486216. DOI: 10.1128/JCM.01597-12. View

Hrabak J, Chudackova E, Walkova R . Matrix-assisted laser desorption ionization-time of flight (maldi-tof) mass spectrometry for detection of antibiotic resistance mechanisms: from research to routine diagnosis. Clin Microbiol Rev. 2013; 26(1):103-14. PMC: 3553667. DOI: 10.1128/CMR.00058-12. View

Lopez-Causape C, Maruri-Aransolo A, Gomis-Font M, Penev I, Castillo M, Mulet X . Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect. 2022; 29(4):538.e7-538.e13. DOI: 10.1016/j.cmi.2022.11.014. View

Cheng C, Zheng F, Rui Y . Rapid detection of blaNDM, blaKPC, blaIMP, and blaVIM carbapenemase genes in bacteria by loop-mediated isothermal amplification. Microb Drug Resist. 2014; 20(6):533-8. DOI: 10.1089/mdr.2014.0040. View

Moya B, Barcelo I, Bhagwat S, Patel M, Bou G, Papp-Wallace K . WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444176. DOI: 10.1128/AAC.02529-16. View

Wenzler E, Deraedt M, Harrington A, Danizger L . Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis. 2017; 88(4):352-354. DOI: 10.1016/j.diagmicrobio.2017.05.009. View

Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y . activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist. 2021; 2(3):dlaa060. PMC: 8210120. DOI: 10.1093/jacamr/dlaa060. View

da Silva Collar G, Moreira N, Becker J, Barth A, Caierao J . Determination of aztreonam/ceftazidime-avibactam synergism and proposal of a new methodology for the evaluation of susceptibility in vitro. Diagn Microbiol Infect Dis. 2024; 109(2):116236. DOI: 10.1016/j.diagmicrobio.2024.116236. View

10.

Malik S, Kaminski M, Landman D, Quale J . Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3. Antimicrob Agents Chemother. 2020; 64(11). PMC: 7577126. DOI: 10.1128/AAC.01221-20. View

10.

Barantsevich E, Churkina I, Barantsevich N, Pelkonen J, Schlyakhto E, Woodford N . Emergence of Klebsiella pneumoniae producing NDM-1 carbapenemase in Saint Petersburg, Russia. J Antimicrob Chemother. 2013; 68(5):1204-6. DOI: 10.1093/jac/dks503. View

11.

Karakonstantis S, Rousaki M, Kritsotakis E . Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics (Basel). 2022; 11(6). PMC: 9220290. DOI: 10.3390/antibiotics11060723. View

11.

Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E . Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Collected as Part of a Global Surveillance Study, 2018 to 2019. Antimicrob Agents Chemother. 2023; 67(5):e0140622. PMC: 10190273. DOI: 10.1128/aac.01406-22. View

12.

Karaiskos I, Galani I, Papoutsaki V, Galani L, Giamarellou H . Carbapenemase producing : implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2021; 20(1):53-69. DOI: 10.1080/14787210.2021.1935237. View

12.

Karlowsky J, Lob S, Chen W, DeRyke C, Siddiqui F, Young K . In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. Int J Antimicrob Agents. 2023; 62(3):106900. DOI: 10.1016/j.ijantimicag.2023.106900. View